Medulloblastoma oncogene aberrations are not involved in tumor initiation, but essential for disease progression and therapy resistance
Konstantin Okonechnikov, Piyush K. Joshi, Verena Körber, Anne Rademacher, Michele Bortolomeazzi, Jan‐Philipp Mallm, Jan Vaillant, Patricia Benites Goncalves da Silva, Britta Statz, Mari Sepp, Ioannis Sarropoulos, Tetsuya Yamada, Andrea Wittmann, Kathrin Schramm, Mirjam Blattner-Johnson, , Stefan Michael Pfister
The paper uses single-cell technologies to show that large-scale chromosomal aberrations drive medulloblastoma initiation, while single-gene oncogenic events like MYC contribute to progression and therapy resistance.
Nature · May 7, 2025Peer-reviewedCancer Biology